↓ Skip to main content

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada

Overview of attention for article published in PharmacoEconomics - Open, March 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
10 X users
facebook
1 Facebook page

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
46 Mendeley
Title
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
Published in
PharmacoEconomics - Open, March 2019
DOI 10.1007/s41669-019-0131-6
Pubmed ID
Authors

Pierre Johansen, Jonas Håkan-Bloch, Aiden R. Liu, Peter G. Bech, Sofie Persson, Lawrence A. Leiter

X Demographics

X Demographics

The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 46 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 15%
Student > Ph. D. Student 5 11%
Student > Master 3 7%
Student > Doctoral Student 2 4%
Other 2 4%
Other 6 13%
Unknown 21 46%
Readers by discipline Count As %
Medicine and Dentistry 17 37%
Nursing and Health Professions 2 4%
Computer Science 1 2%
Immunology and Microbiology 1 2%
Psychology 1 2%
Other 3 7%
Unknown 21 46%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2022.
All research outputs
#5,062,794
of 24,506,807 outputs
Outputs from PharmacoEconomics - Open
#91
of 356 outputs
Outputs of similar age
#100,194
of 356,142 outputs
Outputs of similar age from PharmacoEconomics - Open
#3
of 17 outputs
Altmetric has tracked 24,506,807 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 356 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,142 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.